113. 筋ジストロフィー Muscular dystrophy Clinical trials / Disease details


臨床試験数 : 622 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05126758
(ClinicalTrials.gov)
March 15, 20224/11/2021A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-3)A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular DystrophyMuscular Dystrophies;Muscular Dystrophy, Duchenne;Muscular Disorders, Atrophic;Muscular Diseases;Neuromuscular Diseases;Genetic Diseases, X-Linked;Genetic Diseases, Inborn;Nervous System DiseasesBiological: CAP-1002;Drug: PlaceboCapricor Inc.NULLNot yet recruiting10 YearsN/AMale68Phase 3United States
2NCT04428476
(ClinicalTrials.gov)
July 20, 20209/6/2020Open-label Extension of the HOPE-2 TrialOpen-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy TrialDuchenne Muscular DystrophyBiological: CAP-1002Capricor Inc.NULLActive, not recruiting10 YearsN/AAll13Phase 2United States
3NCT03406780
(ClinicalTrials.gov)
March 4, 201815/1/2018A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyA Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular DystrophyMuscular Dystrophies;Muscular Dystrophy, Duchenne;Muscular Disorders, Atrophic;Muscular Diseases;Neuromuscular Diseases;Nervous System Diseases;Genetic Diseases, X-Linked;Genetic Diseases, InbornBiological: CAP-1002;Drug: PlaceboCapricor Inc.NULLCompleted10 YearsN/AMale18Phase 2United States
4NCT02485938
(ClinicalTrials.gov)
January 201619/6/2015HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular DystrophyDuchenne Muscular Dystrophy;CardiomyopathyDrug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)Capricor Inc.NULLCompleted12 YearsN/AMale25Phase 1/Phase 2United States